4th December 2019 – The global Erectile
Dysfunction Drugs Market size is expected to value at USD 3.2 billion
by 2022. The market is subject to witness a substantial growth due to the
rising health awareness among general population and increase in initiatives
undertaken by local governments and private bodies to promote use of erectile
dysfunction drugs. Growing education levels about use of these products coupled
with rising geriatric population base across the globe is predicted to drive
the growth of erectile dysfunction drugs industry over the forecast period.
Changing food habits and adoption of sedentary lifestyle has led to prevalence
of lifestyle diseases, thus propelling the demand for erectile dysfunction
drugs in the market.
Development of various molecule
combinations and drug delivery techniques like creams and pellets to achieve
higher efficacy and performance are predicted to fuel market demand for the
erectile dysfunction drugs, in the upcoming period. Globally, the erectile
dysfunction drug market is predicted to grow at a higher CAGR over the forecast
period, providing numerous opportunities for market players to invest in
research and development of the erectile dysfunction drugs industry.
Additionally, the rise in number of the patents for key drug molecules and
higher approval rate by regional & international authorities are expected
to stimulate the market growth over the forecast period.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/erectile-dysfunction-drugs-market/request-sample
However, the patent expiration of key
drugs molecules and lack of awareness in the rural areas, particularly in the
Asia Pacific region is expected to limit market growth to a certain extent.
Furthermore, health hazards due to excessive use of the erectile dysfunction
drugs are restraining overall market growth, in the recent years.
Low cost counterfeit drugs and easy
availability are leading to decline in the valuation of the branded erectile
dysfunction drugs. Yet, growing research & development activities and
various regional government reforms couple with public awareness initiatives in
various parts of the globe are projected to foster market expansion in the
upcoming period. In addition, rising healthcare infrastructure activities,
strong economic growth, and rising target population are anticipated to offer
lucrative market opportunities for existing market players in the region.
The erectile dysfunction drugs are
broadly categorized into six major types such as Vitaros, Zydena, Stendra,
Levitra, Cialis, and Viagra. Viagra is considered as one of the fastest growing
segment in the erectile dysfunction drugs market with substantial revue
generation in the last couple of years. The growing popularity of the viagra
drugs market segment is attributed to the widely distributed channels across
the globe. While zydena drugs segment has also witnesses massive growth, in the
recent years owing to the addition of udenafil, also termed as a PDE-5
inhibitor.
The udenafil differs other PDE 5
inhibitors due to capability of remain active for longer duration and minimum
number of side effects such as vision disturbances and muscle pain. The
udenafil is mainly manufactured and sold by Dong-A Pharmaceutical Corporation.
Although, recent research & development activities and introduction of
novel molecules are estimated to foster brand loyalty for Viagra drugs.
The erectile dysfunction drug industry
is divided by region as North America, Europe, Asia-Pacific, Latin America and
Africa. North America has shown major growth in recent years owing to the rise
in the implementation of latest technologies in medicine & pharmaceutical
sector, increase in the approval rate, rising research & development
initiatives regarding the development of innovative drug molecules and
existence of well-established healthcare infrastructure in the region.
Asia-Pacific region is predicted to hold
major market share in the erectile dysfunction drug market with massive growth
in forecast period. Countries such as India, China and South Korea are leading
the Asia-Pacific market with rising occurrence of erectile dysfunction &
infections, increasing base of geriatric population, and significant investment
by leading industry players considering potential growth opportunities in the
region.
The key players in the erectile
dysfunction drugs industry are Apricus Biosciences Incorporations, Bayer AG,
Cristalia Dong-A Pharmaceutical Co., Produtos Quimicos Farmaceuticos Co., Eli
Lilly and Company Co., Pfizer Incorporations, S.K. Chemicals Limited, Meda
Pharmaceuticals Incorporations, and Vivus Co.
Get
in touch
At Million Insights, we work with the
aim to reach the highest levels of customer satisfaction. Our representatives
strive to understand diverse client requirements and cater to the same with the
most innovative and functional solutions.
For
More Information, Visit @ https://www.millioninsights.com
No comments:
Post a Comment